Talphera (TLPH) Change in Account Payables (2010 - 2026)
Talphera (TLPH) posted Change in Account Payables of -$366000.0 for Q2 2026, down 274.29% on a QoQ basis from $210000.0 in Q1 2026, and down 171.76% year-over-year from $510000.0 in Q2 2025.
Powered by 
Analysis
Talphera (TLPH) Change in Account Payables (2010 - 2026) Analysis & Trends
Talphera has reported Change in Account Payables for 17 years, with the latest figure at -$366000.0 in Q2 2026.
- On a quarterly basis, Change in Account Payables fell 171.76% year-over-year to -$366000.0 in Q2 2026; TTM through Jun 2026 was -$529000.0, a 2059.26% decrease from a year earlier, with the FY2025 full-year figure at -$208000.0, up 69.0% from the prior year.
- Change in Account Payables was -$366000.0 for Q2 2026 at Talphera, down from $210000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $526000.0 in Q4 2022, with the low at -$774000.0 in Q2 2023.
- Average Change in Account Payables over 5 years is -$58833.3, with a median of -$12500.0 recorded in 2022.
- The sharpest annual moves came in 2022 and 2023: Change in Account Payables surged 409.41% in 2022, then sank 2191.89% in 2023.
- Over 5 years, Change in Account Payables stood at $526000.0 in 2022, then decreased by 27.38% to $382000.0 in 2023, then decreased by 28.27% to $274000.0 in 2024, then slumped by 66.06% to $93000.0 in 2025, then slumped by 493.55% to -$366000.0 in 2026.
- The last three Change in Account Payables figures came in at -$366000.0 (Q2 2026), $210000.0 (Q1 2026), and $93000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.58 Bn | 192.59 Bn | 7.24 Bn | -70.00 Mn |
| 2 | Gilead Sciences | 180.17 Bn | 176.99 Bn | 6.22 Bn | 18.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.59 Bn | 122.74 Bn | 2.84 Bn | -66.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.61 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.24 Bn | 55.05 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.29 Bn | 49.15 Bn | 52.00 Mn | -8.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.96 Bn | 29.65 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.94 Bn | 30.66 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.38 Bn | 29.38 Bn | 1.16 Mn | 7.11 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | -366,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -366,000.00 |
| Mar 31, 2026 | 210,000.00 |
| Dec 31, 2025 | 93,000.00 |
| Sep 30, 2025 | -466,000.00 |
| Jun 30, 2025 | 510,000.00 |
| Mar 31, 2025 | -345,000.00 |
| Dec 31, 2024 | 274,000.00 |
| Sep 30, 2024 | -412,000.00 |
| Jun 30, 2024 | -471,000.00 |
| Mar 31, 2024 | -62,000.00 |
| Dec 31, 2023 | 382,000.00 |
| Sep 30, 2023 | -283,000.00 |
| Jun 30, 2023 | -774,000.00 |
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 526,000.00 |
| Sep 30, 2022 | -261,000.00 |
| Jun 30, 2022 | 37,000.00 |
| Mar 31, 2022 | 249,000.00 |
| Dec 31, 2021 | -170,000.00 |
| Sep 30, 2021 | 346,000.00 |